Secukinumab

Tax included
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.
MedChemExpress 
HY-P9927

Data sheet

Size
Multiple sizes
Reactivity
Interleukin Related
Application
COVID-19-immunoregulation
CAS
1229022-83-6